ArticleCell death discovery2026
Tumor-associated epilepsy and high expression of xCT shape the proteome of IDH-wildtype glioblastoma.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Given the role of glutamate signaling in glioma-associated epilepsy (GAE) and glioma cell growth, amino acid transporters have gained attention as therapeutic targets. Here, we conducted a comparative analysis of four key transporters-xCT, CD98, EAAT2, and ASCT1-with particular emphasis on xCT, due to the availability of clinically established inhibitors. Protein expression was quantified by immunoblot in snap-frozen tissue of tumor treatment-naïve IDH-mutant and IDH-wildtype gliomas (n = 87) with and without GAE. Quantitative whole-cell proteomics was performed on glioblastoma (GB) from 16 patients stratified for GAE and xCT expression levels. Gliomas from patients with GAE showed significantly higher EAAT2 and ASCT1 levels. In IDH-mutant versus IDH-wildtype glioma, xCT, EAAT2 and ASCT1 were significantly upregulated. Quantitative proteomics revealed 214 significantly regulated proteins in GB with GAE. Upregulated proteins showed enrichment for Gene Ontology (GO) terms involving neurotransmitter and amino acid turnover as well as lipid metabolism. Within the epilepsy group, xCT high-expressing tumors had distinct enrichment patterns. The 231 upregulated proteins partially overlapped with proteins upregulated in the epilepsy cohort, but additionally showed enrichment in pathways related to myelination and synaptic plasticity. In the survival analysis (n = 87), xCT expression and epilepsy did not affect patient survival in either IDH-mutant or IDH-wildtype tumors. Our findings highlight the role of amino acid transporters in GAE. The proteome analysis reveals distinct patterns in GB with epilepsy and also underscores the influence of xCT expression on the tumor proteome, which could inform the development of targeted anti-seizure medication.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.